GSK2636771
- CAS NO.:1372540-25-4
- Empirical Formula: C22H22F3N3O3
- Molecular Weight: 433.42
- MDL number: MFCD22417098
- SAFETY DATA SHEET (SDS)
- Update Date: 2024-11-01 18:09:03
What is GSK2636771?
Description
GSK2636771 is a potent, orally bioavailable, adenosine triphosphate-competitive, selective inhibitor of PI3Kβ with an apparent Ki value of 0.89 nmol/L (IC50 = 5.2 nmol/L), >900-fold selectivity over p110α and p110γ, and >10-fold selectivity over p110δ isoforms, while sparing other PI3K superfamily kinases[1-2].
The Uses of GSK2636771
GSK2636771 is a potent, orally bioavailable, PI3Kβ-selective inhibitor, sensitive to PTEN null cell lines.
in vitro
GSK-2636771 shows selectively inhibitory activity in PTEN null cell lines (human prostate adenocarcinoma PC-3 and breast cancer HCC70) with EC50 of 36 nM and 72 nM, respectively. GSK2636771 significantly decreases cell viability in p110β-reliant PTEN-deficient PC3 prostate and BT549 and HCC70 breast cancer cell lines. It leads to a marked decrease of AKT phosphorylation only in the control prostate and breast cancer cell lines.
References
[1] Mateo, Joaquin , et al. "A first-time-in-human study of GSK2636771, a phosphoinositide 3 kinase beta-selective inhibitor, in patients with advanced solid tumors." Clinical Cancer Research (2017):clincanres.0725.2017.
[2] Sarker, Debashis , et al. "A Phase I, Open-Label, Dose-Finding Study of GSK2636771, a PI3Kβ Inhibitor, Administered with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer." Clinical Cancer Research 27.19(2021):5248-5257.
Properties of GSK2636771
Melting point: | >225°C (dec.) |
Boiling point: | 641.3±55.0 °C(Predicted) |
Density | 1.38 |
storage temp. | -20°C Freezer |
solubility | DMSO (Slightly), Methanol (Slightly) |
pka | -2.70±0.30(Predicted) |
form | Solid |
color | Pale Yellow |
InChI | InChI=1S/C22H22F3N3O3/c1-13-15(4-3-5-18(13)22(23,24)25)12-28-14(2)26-20-17(21(29)30)10-16(11-19(20)28)27-6-8-31-9-7-27/h3-5,10-11H,6-9,12H2,1-2H3,(H,29,30) |
Safety information for GSK2636771
Signal word | Warning |
Pictogram(s) |
Exclamation Mark Irritant GHS07 |
GHS Hazard Statements |
H302:Acute toxicity,oral H315:Skin corrosion/irritation H319:Serious eye damage/eye irritation H335:Specific target organ toxicity, single exposure;Respiratory tract irritation |
Precautionary Statement Codes |
P261:Avoid breathing dust/fume/gas/mist/vapours/spray. P305+P351+P338:IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing. |
Computed Descriptors for GSK2636771
InChIKey | XTKLTGBKIDQGQL-UHFFFAOYSA-N |
SMILES | C1(C)N(CC2=CC=CC(C(F)(F)F)=C2C)C2=CC(N3CCOCC3)=CC(C(O)=O)=C2N=1 |
New Products
SODIUM AAS SOLUTION ZINC AAS SOLUTION BUFFER SOLUTION PH 10.0(BORATE) GOOCH CRUCIBLE SINTERED AQUANIL 5 BERYLLIUM AAS SOLUTION Azithromycin Imp D Azithromycin EP Impurity C Atracurium Besylate EP Impurity D Azithromycin EP Impurity B Azithromycin EP Impurity O Cetirizine Glycerol Ester Impurity HydrochlorideRelated products of tetrahydrofuran
You may like
-
GSK2636771 >95% CAS 1372540-25-4View Details
1372540-25-4 -
Atracurium Besylate EP Impurity CView Details
86293-35-8 -
Atracurium Besylate EP Impurity DView Details
87046-72-8 -
Azithromycin EP Impurity BView Details
307974-61-4 -
Azithromycin EP Impurity CView Details
620169-47-3 -
Azithromycin EP Impurity OView Details
763924-54-5 -
Azithromycin Imp DView Details
612069-26-8 -
Ceftaroline fosamil Acetate HydrateView Details
400827-55-6